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Introduction
Stroke is a major cause of death and disability worldwide.1
Furthermore, patients with acute stroke are at risk of devel-
oping venous thromboembolism (VTE).2–5 In ameta-analysis
involving patients with acute ischemic stroke from several
randomized controlled trials, the incidence of VTE among
stroke patients who did not receive antithrombotic therapy
during follow-up was 17% for asymptomatic and sympto-
matic deep vein thrombosis (DVT).3 Although clinically overt
pulmonary embolism (PE) occurs in only 1% of patients
during the first 14 days after an acute stroke,2,3,6 PE may
account for up to 25 to 50% of deaths after acute stroke.2,7,8 In








Abstract Stroke is associated with a short-term increased risk of subsequent venous throm-
boembolism (VTE). It is unclear to what extent this association is mediated by stroke-
related complications that are potential triggers for VTE, such as immobilization and
infection. We aimed to investigate the role of acute stroke as a trigger for incident VTE
while taking other concomitant VTE triggers into account. We conducted a population-
based case-crossover study with 707 VTE patients. Triggers were registered during the
90 days before a VTE event (hazard period) and in four preceding 90-day control
periods. Conditional logistic regression was used to estimate odds ratios with 95%
confidence intervals (CIs) for VTE according to triggers. Stroke was registered in 30 of
the 707 (4.2%) hazard periods and in 6 of the 2,828 (0.2%) control periods, resulting in a
high risk of VTE, with odds ratios of 20.0 (95% CI: 8.3–48.1). After adjustments for
immobilization and infection, odds ratios for VTE conferred by stroke were attenuated
to 6.0 (95% CI: 1.6–22.1), and further to 4.0 (95% CI: 1.1–14.2) when other triggers
(major surgery, red blood cell transfusion, trauma, and central venous catheter) were
added to the regression model. A mediation analysis revealed that 67.8% of the total
effect of stroke on VTE risk could be mediated through immobilization and infection.
Analyses restricted to ischemic stroke yielded similar results. In conclusion, acute
stroke was a trigger for VTE, and the association between stroke and VTE risk appeared
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be particularly high during the first three months after
stroke.4,5 For instance, data from the Tromsø Study revealed
a 20- and 11-fold increased risk of VTE in the first and
subsequent two months after ischemic stroke, respectively,
with a rapid decline of the risk estimates thereafter.5
Even though the association between stroke and subse-
quent risk of VTE is well established,2–5 the mechanism
underlying this association is not fully understood, as data
on explanatory factors are scarce. Confounding due to the
presence of common atherosclerotic risk factors seems to
poorly explain this association, since among the athero-
sclerotic risk factors, only advancing age and obesity have
consistently been associated with VTE.9 If causal, the asso-
ciation between stroke (exposure) and VTE (outcome) may
be explained by factors that are a consequence of stroke
(intermediates or mediators), which in turn could increase
the risk of VTE.10 Such an effect of the exposure on the
outcome is indirect as it acts through the intermediate
variable, whereas the effect that is not explained by the
intermediate is referred to as a direct effect.10
Neurological and medical complications can frequently
arise as consequences of acute stroke, and lead to prolonged
hospitalization, poorer functional outcome, and increased
mortality rate of stroke patients.11–13 Neurological deficits
entailing immobilization and infections are common compli-
cations after stroke11,13 that have thepotential to trigger a VTE
event,14–16 and could therefore be intermediates in the chain
of causation between stroke and VTE. Indeed, the short-term
increased risk of VTE after acute stroke5 suggests that stroke-
related complications are main contributors to the VTE risk in
stroke patients. In the relationship between stroke and VTE,
infection can also act as confounder, particularly pneumonia
that has been reported to be associated with increased risk of
both ischemic stroke and VTE.17 Additionally, pneumonia is
one of the most frequent medical complications following
acute stroke,12,13 and multiple factors have been shown to
independently contribute to stroke-related pneumonia,
including dysphagia with aspiration of oropharyngeal mate-
rial, advancing age, and severity of poststroke disability.18,19
Enhanced knowledge on howmuch immobilization and infec-
tionmediate the association between stroke and risk of VTE is
clinically relevant, since it may provide opportunity for tar-
geted interventions to improve prevention of VTE after stroke.
In this study, we aimed to assess the role of acute stroke as a
trigger for VTE while taking other concomitant VTE triggers
into account, and to investigate towhat extent immobilization
and infection couldmediate the effect of stroke onVTE risk. For
this purpose, we conducted a case-crossover study with inci-
dent VTE cases recruited from the general population. This
studydesign relies on intra-personcomparison, since each case
serves as his or her own control, and it is suited to investigate
the effects of transient exposures on acute outcomes.20
Methods
Study Population
Participants were recruited from the fourth survey of the
Tromsø Study, a single-center, population-based cohort
study, details of which have been described elsewhere.21
Briefly, in 1994 to 1995, all inhabitants aged>24 years living
in the municipality of Tromsø were invited, and 27,158 (77%
of the eligible population) participated. Incident VTE events
among the study participantswere recorded from the date of
enrollment (1994–1995) until December 31, 2012.22 All
incident VTE eventswere identified by searching thehospital
discharge diagnosis registry, the autopsy registry, and the
radiology procedure registry at the University Hospital of
North Norway. The University Hospital of North Norway is
the only hospital in the region, and all hospital care and
relevant diagnostic radiology is provided exclusively by this
hospital. The medical record for each potential case of VTE
was reviewed by trained personnel, and an episode of VTE
was confirmed and registered as a validated VTE when
clinical signs and symptoms of DVT or PE were combined
with objective confirmation by radiological procedures, and
resulted in a VTE diagnosis requiring treatment, as described
in detail previously.22 The study was approved by the regio-
nal committee for research ethics, and all participants gave
their informed written consent to participate.
Study Design
A case-crossover study was conducted to investigate the role
of acute stroke as a trigger for VTE. This design uses data on
cases only, that is, on individuals who have experienced the
outcome of interest.20 In most observational study designs,
confounding remains a methodological challenge. In the
case-crossover study, individuals serve as their own controls,
and all potential fixed confounders, such as chronic condi-
tions, comorbidities, and anthropometric and genetic fac-
tors, are largely controlled for through the study design.20 As
previously described,16 the study population comprised all
incident VTE cases (n ¼ 707) that occurred among the
participants of the Tromsø Study during 1994 to 2012. In
this study, the hazard (i.e., risk) periodwas defined as the 90-
day period before the date of the incident VTE.15,16 Expo-
sures during the hazard period were compared with expo-
sures occurring during the four previous 90-day control
periods (►Fig. 1). The length of these hazard and control
periods was predefined based on the definition of provoking
factors, as described by Kearon et al.23 A 90-day washout
period between the control and the hazard periods was
included to avoid carry-over effects. For each VTE case,
trained medical personnel searched the hospital medical
records for relevant risk factors, diagnostic procedures,
surgical and medical treatment, laboratory tests and diag-
noses during hospital admissions, day care, and outpatient
clinic visits in any of the control or hazard periods. We did
not have access to medical records from general practice.16
Definition of Transient Risk Factors for VTE
A transient risk factor, or trigger, was defined by its presence
during the 90 days before a VTE event (hazard period) and/or
in four preceding 90-day control periods.16 If an exposure
occurred over several days, it was considered to have
occurred if any of the days of the exposure fell within the
specified 90-day time period. Stroke was defined in the
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presence of the diagnosis of ischemic, hemorrhagic, or
unclassified stroke in the medical records. The other VTE
triggers were recorded as previously described.16 Briefly,
immobilization was defined by the presence of bed rest for
3 days or more, ECOG (Eastern Cooperative Oncology Group)
score of 4, or other immobilizing factors specified in the
patient’s medical record (e.g., confinement to wheelchair).
Infection was recorded if an acute infection was noted by a
physician in the patient’s medical record, and this definition
included both community-acquired infections that required
hospital admission and hospital-acquired infections. Infec-
tion was defined as respiratory tract infection (RTI), urinary
tract infection, and other infections. As RTI and PE may have
similar symptoms, some PEs could initially have been diag-
nosed as RTI. Therefore, all cases with RTI and PE were
thoroughly reevaluated by a specialist in infectious diseases,
and the diagnoses of RTI that were most likely incorrect
(n ¼ 8) were recoded as “no RTI.” Red blood cell transfusion,
central venous catheterization, trauma, and major surgery
were recorded if noted in the medical record.
Statistical Analyses
Statistical analyses were performed using STATA version 15.0
(Stata Corporation, College Station, Texas, United States). We
used conditional logistic regression to calculate odds ratios
(ORs) with 95% confidence intervals (CIs) as estimates of the
relative risk of VTE according to the presence of stroke,
immobilization, and acute infection, with the reference cate-
gory being defined as no exposure to the aforementioned
variables. In model 1, we calculated the crude association
between stroke and VTE. Model 2 was adjusted for the pre-
sence of immobilization and infection. In model 3, we addi-
tionally adjusted for major surgery, red blood cell transfusion,
trauma, and central venous catheter, since these variables are
potential triggers forVTE that often coexistwithboth infection
and immobilization.15,16 Risk estimates for VTE associated
with immobilization and infection were also presented, using
the same models. However, for immobilization, models were
adjusted for stroke and infection, and for infection, models
were adjusted for stroke and immobilization.
Under the assumption that immobilization and infection
were a consequence of acute stroke, we further examined to
what extent both factors could mediate the association
between stroke and VTE using the method developed by
Karlson, Holm, and Breen (KHB method).24 The technical
details andmathematical proofs of this method are available
elsewhere.24 Briefly, this method estimates all effects (i.e.,
direct, indirect, and total) on the same scale and the coeffi-
cients in conditional logistic regression models are not
affected by rescaling, particularly when the total effect is
decomposed into the direct and indirect effects. This prop-
erty allows us to compare the coefficients without any scale
identification issues. Additionally, the KHB method has the
important feature that it can handle more than onemediator
simultaneously. This method also enables to decompose the
contribution from the different mediators while adjusting
for other factors.
In addition to the overall analyses, we performed sub-
group analyses stratified by the localization of the thrombo-
tic event, i.e., DVT and PE with or without DVT. We repeated
all analyses considering only ischemic stroke as an exposure.
For sensitivity purposes, we also conducted analyses for
overall VTE where subjects with active cancer at the time
of VTE diagnosis were excluded. To account for seasonality of
infection in the association between acute infection and risk
of VTE, we performed a sensitivity analysis restricting the
comparison of the hazard periodwith the control period that
occurred 12 to 15months before VTE. According to our study
design (►Fig. 1), this particular control period for each study
participant represents exactly the same calendar period
1 year prior to the VTE event (i.e., the exactly same season
as the hazard period).
Results
►Table 1 shows the characteristics of the study participants
at the time of VTE, and the distribution of VTE triggers in the
hazard and control periods. Median age at VTEwas 71 years,
and 53.6% were women. Among the VTE events, 57.7% were
DVT and 42.3% were PE with or without DVT. In 19.1% of the
cases, VTE occurred during hospitalization for other condi-
tions. All potential triggers for VTE, including stroke,
occurredmore frequently in the hazard than control periods.
Stroke occurred in 30 of the 707 (4.2%) hazard periods, and in
Fig. 1 Case-crossover study design. A transient risk factor, or trigger, was recorded for each case of venous thromboembolism (VTE) in the 90-
day hazard period prior to the event, and in four preceding 90-day control periods, separated by a 90-day washout period.
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6 of the 2,828 (0.2%) control periods. Among the stroke
events (n ¼ 36), 23 were recorded as ischemic (20 occurred
in the hazard and 3 in the control periods), 9 as hemorrhagic
(7 occurred in the hazard and 2 in the control periods), and 4
as unclassified (3 occurred in the hazard and 1 in the control
periods). Among the 30 cases with stroke in the hazard
period, 24 (80%) developed their VTE during the hospitaliza-
tion with stroke, whereas 6 (20%) developed their VTE in the
community after being discharged with stroke. Thrombo-
prophylaxis with low-molecular weight heparin (LMWH)
was prescribed in 138 of the 707 (19.5%) hazard periods, and
in 78 of the 2,828 (2.8%) control periods. LMWH was pre-
scribed in 13 of the 30 (43.3%) patients with stroke in the
hazardperiod, and in none of the 6 patientswith stroke in the
control periods.
Frequencies of stroke, immobilization, and infection dur-
ing the hazard and control periods, as well as risk estimates
for VTE associated with each variable, are described
in ►Table 2. In unadjusted models, stroke, immobilization,
and infection were all associated with an increased risk of
VTE. The risk of VTE conferred by strokewas high, with an OR
of 20 (95% CI: 8.3–48.1). However, after adjustment for
immobilization and infection (model 2), the association
between stroke and VTE was markedly attenuated, resulting
in an OR for VTE of 6.0 (95% CI: 1.6–22.1). Of note, when
immobilization and infection were added separately to the
regression models, the effect of stroke on the risk of VTEwas
attenuated to a similar extent when adjusted for immobili-
zation only (OR: 11.5, 95% CI: 3.2–41.0) or infection only (OR:
9.0, 95% CI: 3.1–26.0). When the other VTE triggers (i.e.,
Table 1 Characteristics of the study participants
Characteristics At time of VTE diagnosis (n ¼ 707)
Median age, years  SD 71  14
Female sex (n, %) 379 (53.6)
Deep vein thrombosis (n, %) 408 (57.7)
Pulmonary embolisma (n, %) 299 (42.3)
VTE during hospitalization (n, %) 135 (19.1)




Strokeb (n, %) 30 (4.2) 6 (0.2)
Immobilizationc (n, %) 222 (31.4) 57 (2.0)
Infection (n, %) 267 (37.8) 107 (3.8)
Major surgery (n, %) 118 (16.7) 88 (3.1)
Red blood cell transfusion (n, %) 82 (11.6) 28 (1.0)
Trauma (n, %) 71 (10.0) 25 (0.9)
Central venous catheter (n, %) 56 (7.9) 17 (0.6)
Abbreviation: SD, standard deviation; VTE, venous thromboembolism.
aPulmonary embolism with or without deep vein thrombosis.
bIschemic, hemorrhagic, or unclassified stroke.
cBed rest for 3 days, Eastern Cooperative Oncology Group score of 4, or other immobilizing factors specified in the patient’s medical record (e.g.,
confinement to wheelchair).













Stroke 30 (4.2) 6 (0.2) 20.0 (8.3–48.1) 6.0 (1.6–22.1) 4.0 (1.1–14.2)
Immobilization 222 (31.4) 57 (2.0) 66.7 (37.3–119.4) 37.0 (19.9–69.0) 26.5 (14.0–50.1)
Infection 267 (37.8) 107 (3.8) 24.2 (17.2–34.0) 14.3 (9.9–20.9) 11.7 (7.9- 17.2)
Abbreviations: CI, confidence interval.
Note: For immobilization, infection, and stroke, the reference category was defined as no exposure to the trigger.
Model 1: unadjusted odds ratios.
Model 2: adjusted for the other variables in this table.
Model 3: adjusted as in model 2 with addition of major surgery, trauma, red blood cell transfusion, and central venous catheter.
a707 cases, four control periods for each case.
TH Open Vol. 3 No. 1/2019
Role of Stroke as a Venous Thromboembolism Trigger Morelli et al. e53
major surgery, trauma, red blood cell transfusion, and central
venous catheter) were introduced in a third model along
with immobilization and infection, risk estimates for VTE
associated with stroke were further attenuated to 4.0 (95%
CI: 1.1–14.2).
Next, we analyzed the magnitude of the mediating effect of
immobilizationand infectiononthe relationshipbetweenstroke
and VTE. In a mediation analysis adjusted for major surgery,
trauma, red blood cell transfusion, and central venous catheter,
about two-thirds (67.8%) of the total effect of stroke on VTE risk
was due to amediating effect (i.e., indirect effect) acting through
immobilization and infection (►Supplementary Table S1).
With respect to the mediating effect, 56.7% was attributable to
immobilization and 43.3% to infection.
►Table 3 shows frequencies and ORs for stroke, immobi-
lization, and infection in subjects with DVT and PE sepa-
rately. In unadjusted models, the thrombosis risk conferred
by stroke was higher for DVT (OR: 24.0, 95% CI: 7.1–81.5)
than for PE (OR: 16.0, 95% CI: 4.5–56.7). Still, the association
between stroke and DVT or PE was again substantially
attenuated after adjustments for all VTE triggers (model 3),
with ORs of 4.0 (95% CI: 0.6–27.9) and 4.1 (95% CI: 0.7–23.0),
respectively.
When the analysis was restricted to subjects exposed
to ischemic stroke, the results were similar to those
obtained when all types of stroke were taken into account,
for overall VTE, DVT and PE, and in mediation analysis for
overall VTE (►Supplementary Tables S2–S4). However,
after adjustment for immobilization and infection (model
2) or for all VTE triggers (model 3), ORs for VTE conferred
by ischemic stroke were attenuated to 4.9 (95% CI: 0.8–
29.4) and 3.7 (95% CI: 0.7–18.7), respectively. Among the
707 cases, 176 (24.9%) had active cancer at the time of VTE
diagnosis. Exclusion of these patients yielded similar
results to the main analysis (►Supplementary Table S5).
When the hazard period was compared with the control
period that occurred 12 to 15 months before VTE (i.e., the
control period that represented the same seasons as the
hazard period), the OR for VTE associated with infection
remained high (OR: 18.3, 95% CI: 10.7–31.3) and did not
significantly differ from the overall OR where all control
periods were taken into account (OR: 24.2, 95% CI: 17.2–
34.0; ►Table 2).
Discussion
In this population-based case-crossover study of 707
patients with incident VTE, we investigated the role of
acute stroke as a VTE trigger, and found that stroke was
associated with a substantial increased risk of subsequent
VTE, with an OR of 20.0. However, the impact of stroke on
the risk of VTE was largely attenuated after adjustments for
other VTE triggers, mainly immobilization and infection,
which are both common stroke-related complications.
Indeed, almost 68% of the total effect of stroke on the risk
of VTE was indirect, due to the mediating effect of immo-
bilization and infection. It is noteworthy that even after
adjustments for all the potential VTE triggers (i.e., immo-
bilization, infection, surgery, red blood cell transfusion,
trauma, and central venous catheter), the risk of VTE
associated with stroke remained elevated, with an OR of
4.0. Analyses restricted to subgroups (i.e., DVT and PE) or
ischemic stroke yielded similar results. Our findings suggest
that immobilization and infection are important intermedi-
ates for the association between stroke and subsequent risk
of VTE, but conditions related to stroke other than these
intermediates studied could still play a considerable role in
the risk of VTE.
Table 3 Distribution of triggers in the hazard and control periods and odds ratios (ORs) of deep vein thrombosis and pulmonary
embolism












Stroke 18 (4.4) 3 (0.2) 24.0 (7.1–81.5) 8.6 (1.3–57.3) 4.0 (0.6–27.9)
Immobilization 143 (35.0) 38 (2.3) 73.6 (34.4–157.4) 40.5 (17.9–91.6) 29.9 (13.1–68.2)
Infection 143 (35.0) 60 (3.7) 19.9 (13.0–30.6) 8.8 (5.4–14.3) 6.9 (4.1–11.6)












Stroke 12 (4.0) 3 (0.3) 16.0 (4.5–56.7) 4.8 (0.8–27.3) 4.1 (0.7–23.0)
Immobilization 79 (26.4) 19 (1.6) 57.0 (23.0–141.0) 36.5 (13.5–98.4) 27.0 (9.7–75.3)
Infection 124 (41.5) 47 (3.9) 32.4 (18.2–57.5) 25.8 (13.8–48.0) 21.5 (11.4–40.5)
Abbreviations: CI, confidence interval.
Note: For immobilization, infection, and stroke, the reference category was defined as no exposure to the trigger.
Model 1: unadjusted odds ratios.
Model 2: adjusted for the other variables in this table.
Model 3: adjusted as in model 2 with addition of major surgery, trauma, red blood cell transfusion, and central venous catheter.
a408 deep vein thrombosis cases, four control periods for each case; 299 pulmonary embolism cases, four control periods for each case.
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Studies aimed at investigating the mechanism underlying
the association between stroke and subsequent risk of VTE
have been scarce thus far. Recently, we have demonstrated in
the Tromsø Study5 that shared atherosclerotic risk factors are
an unlikely explanation for the association between stroke
and VTE due to the short-term risk of VTE after ischemic
stroke, and to the marginal impact that adjustments for
atherosclerotic risk factors had on this association. Findings
from the present study further suggest that immobilization
and infection are main explanatory factors for the associa-
tion between stroke and VTE, accounting for about two-
thirds of the total effect of stroke on the risk of VTE. To the
best of our knowledge, this is the first study that has
evaluated the role of stroke as a VTE trigger using a case-
crossover design. Of note, our results are consistent with
previous reports in which stroke-related factors, such as
severity of neurological impairment25 and lower limb par-
esis,26 were significant contributors to the VTE risk in stroke
patients.
Immobilization and infection may contribute to the
increased risk of VTE after stroke either via prolongation
of hospital stay or by themselves, probably with the involve-
ment of multiple coexisting pathways. Immobilization is an
important risk factor for VTE14 due to venous stasis. Stroke
patients are often temporarily immobilized owing to bed rest
or neurological deficits of affected limbs,26,27 and thus more
prone to venous thrombus formation. Infections, particularly
urinary tract infection and pneumonia, are leading medical
complications after stroke,12 and stroke severity is an inde-
pendent predictor of both urinary tract infection28 and
pneumonia.29 In a meta-analysis involving 137,817 stroke
patients, the overall rate of infection in the acute phase of
stroke was 30%, and among those admitted to an intensive
care unit, rates were as high as 45%.13 Infection can increase
the risk of VTE either through a systemic activation of the
coagulation system17 or through immobilization/bed rest.30
Potential mechanisms related to the coagulation system
underlying the link between infection and VTE include
upregulation of tissue factor, a main trigger of blood coagu-
lation in vivo, and downregulation of anticoagulant factors
(e.g., activated protein C).17 Infection is also associated with
the formation of neutrophil extracellular traps (NETs), which
are produced to allow neutrophils to trap and disarm
microbes in the extracellular environment.31 NETs provide
a new link between innate immunity and thrombosis and
have been shown to contribute to experimental DVT.31 Cell-
free DNA is a key component of NETs that may exert harmful
effects by triggering blood coagulation via the contact path-
way, in a FXII- and FXI-dependent manner.32 Finally, the
relationship between infection and immobilization is bidir-
ectional, as immobilization is a risk factor for infection,
particularly pneumonia,33 and their combination has been
suggested to have synergistic effects on VTE risk.16
It is of interest that the risk of VTE conferred by stroke,
albeit attenuated, remained considerably elevated even after
adjustment for immobilization and infection (OR: 6.0), and
further for the other VTE triggers (OR: 4.0). In a case-cross-
over study, all fixed confounders that do not vary over the
study periods are largely controlled for through the design,20
and are therefore unlikely to influence our results. The
association between stroke and VTE that nevertheless per-
sisted after multivariable adjustment could be due to other
unknown or unmeasured transient factors related to stroke
itself that had the potential to increase the risk of VTE. For
instance, previous studies have shown that levels of several
biomarkers of coagulation activation were increased after
acute stroke and associated with stroke severity.34,35 A
hypercoagulable state is a key pathway for venous thrombus
formation,36 and could have accounted for part of the
observed effect of acute stroke on VTE risk. However, our
study was not designed to evaluate the validity of this
proposed mechanism, and it remains to be clarified to
what extent a hypercoagulable state poststroke may con-
tribute to the subsequent risk of VTE.
Our findings may have some clinical implications. Given
the potential role of infection and immobilization in mediat-
ing the relationship between stroke and VTE, their preven-
tion through improvement in patient care and rehabilitation
programs may lower the risk of VTE after acute stroke. For
instance, the addition of a passive turning and mobilization
program to usual care effectively reduced the incidence of
pneumonia during the acute phase of stroke.33 Our findings
also suggest the need to consider not only immobilization
but also infection in clinical decision making regarding
thromboprophylaxis after stroke. For prevention of VTE in
patients with acute ischemic stroke and restricted mobility,
current guidelines recommend the use of prophylactic doses
of LMWH or unfractionated heparin, which should be
initiated as early as possible, and continued throughout
the hospital stay or until the patient has regainedmobility.37
A meta-analysis of randomized clinical trials implied that
prophylaxis with LMWH or unfractionated heparin in
patients with acute ischemic stroke had the potential to
reduce the incidence of symptomatic DVT by 70% and the
incidence of fatal and nonfatal PE by 30%.37 Still, data from
real-world practice have shown that less than half of the
patients hospitalized for ischemic stroke at risk of VTE
receive any form of thromboprophylaxis.38,39 Uncertainty
on the identification of high risk groups for VTE, and the
perceived bleeding risk associatedwith anticoagulation, may
explain, at least in part, the current underuse of thrombo-
prophylaxis after acute stroke. Indeed, decisions on throm-
boprophylaxis and its duration after acute stroke could be a
dilemma in the clinics, as the benefits of prophylaxis with
LMWH in reducing the risk of VTE may be offset by major
bleeding,40,41 including intracerebral hemorrhage.40 In the
randomized controlled EXCLAIM trial, which involved 389
patients with acute ischemic stroke, extended-duration pro-
phylaxis with LMHW was associated with a reduction in the
incidence of VTE but also with an increase in major bleed-
ing.41 An accurate prediction of VTE after stroke may guide
clinical decisions, and thereby increase the use of antic-
oagulants in patients with a favorable benefit-to-harm ratio
for thromboprophylaxis. However, data on prediction of VTE
in stroke patients are scarce. Currently existing risk predic-
tion algorithms for VTE discriminated poorly between
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immobile stroke patients at high and low risk of VTE,42 or
involved a limited number of patients, who were all
Asians.43,44 Taken together, our results suggest that infection
plays an important role in the development of VTE after
acute stroke, a finding that requires confirmation by future
investigation in a cohort of stroke patients. The addition of
infection to future prediction models may improve the
identification of stroke patients at a substantially high risk
of developing VTE, who would benefit most from thrombo-
prophylaxis with anticoagulation.
The strengths of our study include the high attendance rate
in thepopulation-basedcohortwhere thecaseswere recruited
from, the complete and validated registry of VTE events, and
the study design enabling us to focus on transient risk factors
while controlling for potential fixed confounders, as partici-
pants serve as their own controls.20 Some limitations should
be addressed as well. First, in this study, information on
exposure to VTE triggers was obtained during the last
90 days before each admission, but without dissecting the
temporal sequence between them. Analyses of the present
study assume that stroke preceded the occurrence of immo-
bilization, infection, and the other VTE triggers studied. How-
ever, although it is unlikely, we cannot rule out that acute
stroke, in somecases,mayhavefollowed theotherVTEtriggers
during hospitalization. Therefore, ourfindings shouldbe inter-
preted with caution, and they need to be confirmed by future
prospective cohort studies involving stroke patients, in which
a clear temporal sequence between exposure, intermediate,
and outcome is determined through the design. Second, since
exposure to strokewasbasedondataobtained fromthe review
of medical records, with no further validation by an indepen-
dent end-point committee, misclassification cannot be ruled
out. Nevertheless, thedefinitionof stroke is currently basedon
objective diagnostic criteria, in which radiological procedures
play a central role,45 thereby making misclassification of
stroke diagnosis unlikely. Third, information on exposures in
our case-crossover study might be subject to bias, as doctors
couldbemoreawareofVTE-risk factorswhenVTE is suspected
than during admissions for other conditions in the control
periods. For instance, as immobilization is a well-known risk
factor for VTE, immobilization could have beenmore recorded
when VTEwas suspected. If so, the effect of immobilization on
the risk of VTE and its role as a mediator for the association
between stroke andVTEmight be overestimated. In this study,
we only had access to medical records from hospital, and
therefore less severe infections and conditions leading to
immobilization managed solely in general practice were not
included in our analysis. A higher number of underreported
exposure to immobilization and infection (due to manage-
ment by general practice) in the control than hazard periods
could also have led to an overestimation of the impact of these
exposures onVTE risk. Taken together, potentialmisclassifica-
tion of immobilization and infection during the hazard and
control periods might have limited the internal validity of our
results. Fourth, even if fixed confounders are controlled for
through the study design, other (unknown/unmeasured) tran-
sient risk factors might have influenced the relationship
between stroke and VTE, as we have previously pointed out.
Fifth, unfortunately, we did not have information about sub-
types of ischemic stroke, stroke severity, and medications
prescribed according to stroke subtype, such as the use of
anticoagulants among patientswith cardioembolic stroke. The
aforementioned information would allow a more detailed
assessment of the role of stroke as a VTE trigger. Sixth, the
present findings should be interpreted with caution, as low
numbers of exposure to stroke limited the statistical power of
our results in somesubgroups, particularlywhenassessing the
role of ischemic stroke as a VTE trigger.
In conclusion, acute strokewasa trigger forVTE in this case-
crossover study, but our findings suggest that the association
between acute stroke and subsequent risk of VTE is largely
mediated by the presence of immobilization and infection.
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